Literature DB >> 2678869

Changes in plasma renin activity and aldosterone concentration in response to endothelin injection in dogs.

A Otsuka1, H Mikami, K Katahira, T Tsunetoshi, K Minamitani, T Ogihara.   

Abstract

The effects of endothelin on the renin-aldosterone system were examined by injecting it intravenously at low (40 pmol/kg) and high (400 pmol/kg) doses into pentobarbital-anesthetized dogs. Plasma renin activity and aldosterone concentration together with hemodynamic parameters were measured before and 60 min after endothelin injection. The lower dose of endothelin induced no significant increase in mean blood pressure or total peripheral resistance. It caused a slight decrease of plasma renin activity from 10.3 +/- 1.6 to 5.9 +/- 1.3 micrograms.l-1.h-1 (p less than 0.1) and a decrease of aldosterone concentration from 364 +/- 68 to 231 +/- 58 ng/l (p less than 0.05) with an increase in total peripheral resistance (p less than 0.05), but it did not cause any clear change in the plasma renin activity or aldosterone concentration. Thus, endothelin increases the blood pressure mainly by vasoconstriction. The finding of a slight decrease in the plasma renin activity after the lower dose of endothelin, together with our previous finding that endothelin inhibits renin release from isolated rat glomeruli, suggests that endothelin inhibits renin release in vivo. With the higher dose of endothelin, stimulation of renin release secondary to renal vasoconstriction might have counteracted the direct inhibitory action of endothelin. The decrease in aldosterone concentration may have been due to the direct inhibitory action of endothelin on aldosterone release or it may be a secondary effect induced by suppression of plasma renin activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2678869     DOI: 10.1530/acta.0.1210361

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  8 in total

Review 1.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 3.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 4.  Inhibition of ENaC by endothelin-1.

Authors:  Andrey Sorokin; Alexander Staruschenko
Journal:  Vitam Horm       Date:  2015-03-06       Impact factor: 3.421

5.  Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect.

Authors:  M D'Alto; C D Vizza; E Romeo; R Badagliacca; G Santoro; R Poscia; B Sarubbi; M Mancone; P Argiento; F Ferrante; M G Russo; F Fedele; R Calabrò
Journal:  Heart       Date:  2006-11-29       Impact factor: 5.994

Review 6.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

7.  Haemodynamic effects of human alpha-calcitonin gene-related peptide following administration of endothelin-1 or NG-nitro-L-arginine methyl ester in conscious rats.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett; R Foulkes; B Hughes
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

Review 8.  Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease.

Authors:  Radko Komers; Horacio Plotkin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-03-23       Impact factor: 3.619

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.